These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22730859)

  • 1. Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution.
    Ojito JW; Hannan RL; Burgos MM; Lim H; Huynh M; Velis E; Arocha M; Tirotta CF; Burke RP
    J Extra Corpor Technol; 2012 Mar; 44(1):15-20. PubMed ID: 22730859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability.
    Dirkmann D; Nagy E; Britten MW; Peters J
    BMC Anesthesiol; 2019 Sep; 19(1):174. PubMed ID: 31492108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation.
    Chia S; Van Cott EM; Raffel OC; Jang IK
    Thromb Haemost; 2009 Mar; 101(3):535-40. PubMed ID: 19277416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does a delay in performing an activated clotting (ACT) test really matter? A study in nonheparinized blood and a single ACT machine.
    Philip BM; Brock-Utne JG; Lemmens HJ; Jaffe RA; Shuttleworth PE
    J Extra Corpor Technol; 2008 Sep; 40(3):193-5. PubMed ID: 18853832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluations of activated clotting time technologies require understanding activating clotting time system differences.
    Zucker ML
    J Extra Corpor Technol; 2013 Mar; 45(1):58-9. PubMed ID: 23691787
    [No Abstract]   [Full Text] [Related]  

  • 7. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
    Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
    Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to letter "Evaluations of activated clotting time technologies require understanding activating clotting time system differences" by Marcia L. Zucker.
    Hannan RL; Ojito JW
    J Extra Corpor Technol; 2013 Mar; 45(1):60. PubMed ID: 23691788
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of ACT point-of-care measurements: repeatability and agreement.
    Bosch YP; Ganushchak YM; de Jong DS
    Perfusion; 2006 Jan; 21(1):27-31. PubMed ID: 16485696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of four activated clotting time measurement devices in cardiac surgery with cardiopulmonary bypass.
    Li H; Serrick C; Rao V; Yip PM
    Perfusion; 2021 Sep; 36(6):610-619. PubMed ID: 32885714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of three activated clotting time point-of-care systems in cardiac surgery: reinforcing available evidence.
    Solís Clavijo D; Cotano AO; Peña NA; Caballero Gálvez S; Arellano Núñez F; Carballo Caro JM; Muñoz-Cacho P; Tocón Alé C
    Perfusion; 2022 Oct; 37(7):711-714. PubMed ID: 34109886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
    Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
    J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point-of-Care Measurement of Kaolin Activated Clotting Time during Cardiopulmonary Bypass: A Single Sample Comparison between ACT Plus and i-STAT.
    Vranken NPA; Theelen AJAJ; Orbons T; Barenbrug PJC; Weerwind PW
    J Extra Corpor Technol; 2021 Mar; 53(1):57-61. PubMed ID: 33814607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraoperative Monitoring of Heparin: Comparison of Activated Coagulation Time and Whole Blood Heparin Measurements by Different Point-of-Care Devices with Heparin Concentration by Laboratory-Performed Plasma Anti-Xa Assay.
    Thompson TZ; Kunak RL; Savage NM; Agarwal S; Chazelle J; Singh G
    Lab Med; 2019 Oct; 50(4):348-356. PubMed ID: 31053856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Heparin Anticoagulation Measured Using i-STAT and Hemochron Activated Clotting Time.
    Maslow A; Chambers A; Cheves T; Sweeney J
    J Cardiothorac Vasc Anesth; 2018 Aug; 32(4):1603-1608. PubMed ID: 29503117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory.
    Doherty TM; Shavelle RM; French WJ
    Catheter Cardiovasc Interv; 2005 Jul; 65(3):330-7. PubMed ID: 15864806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.
    Despotis GJ; Filos KS; Levine V; Alsoufiev A; Spitznagel E
    Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interchangeability of activated clotting time values across different point-of-care systems.
    Thenappan T; Swamy R; Shah A; Nathan S; Nichols J; Bond L; Jolly N
    Am J Cardiol; 2012 May; 109(9):1379-82. PubMed ID: 22341924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test.
    Paniccia R; Fedi S; Carbonetto F; Noferi D; Conti P; Bandinelli B; Giusti B; Evangelisti L; Pretelli P; Palmarini MF; Abbate R; Prisco D
    Anesthesiology; 2003 Jul; 99(1):54-9. PubMed ID: 12826842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
    Hellstern P; Bach J; Simon M; Saggau W
    J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.